Navigation Links
NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
Date:11/7/2008

FT. MYERS, Fla., Nov. 7 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that President and Chief Scientific Officer, Bob Gasparini, will present at the Rodman & Renshaw 10th Annual Healthcare Conference being held from November 10-12, 2008 at the New York Palace Hotel in New York City. The conference will showcase over 350 small and microcap public life sciences and biotech companies. Gasparini and other senior executives of attending companies will make presentations to portfolio managers and analysts on their business strategy and outlook. One-on-one meetings with interested parties will also be arranged during the three-day conference.

NeoGenomics is scheduled to present on Monday, November 10th at 5:20 PM EST. A live audio webcast of the presentation can be accessed at http://www.wsw.com/webcast/rrshq14/ngnm.ob . A PowerPoint presentation and a link to the webcast can also be accessed through the investor relations section of the NeoGenomics website at http://www.neogenomics.org at the time of the conference. The webcast will be available for three months.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org .

Interested parties can also access additional investor relations material from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/ or from Hawk Associates at http://www.hawkassociates.com . An investment profile about NeoGenomics may be found at http://www.hawkassociates.com/clients/additional/index.cfm?client_id=10 .

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.


'/>"/>
SOURCE NeoGenomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
2. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
3. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
4. NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... and CAMBRIDGE, Mass. ... , Dec. 4, 2016 SystemOne, ... connected diagnostics software platforms for the developing world, ... "Anywhere. Care.™" a reality with its portable and ... entered into a development and license agreement to ...
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... today announced the submission of a Marketing Authorization Application (MAA) ... biosimilar candidate to Avastin ® (bevacizumab). The companies believe ... the EMA. "The submission of ABP 215 ... to expand our oncology portfolio," said Sean E. Harper ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) ... Antonio Breast Cancer Symposium. Using molecular test results from tumors with previously ...
(Date:12/2/2016)... ... 2016 , ... DrugDev believes the only way to achieve real ... All three tenets were on display at the 2nd Annual DrugDev User Summit (hosted ... CRO and site organizations to discuss innovation and the future of clinical research. ...
Breaking Biology Technology:
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
Breaking Biology News(10 mins):